Novo wins EU recommendation for two-in-one diabetes drug

July 25, 2014 12:20 PM

10 0

Novo wins EU recommendation for two-in-one diabetes drug

LONDON (Reuters) - A Novo Nordisk drug combining its long-acting insulin degludec with its type 2 diabetes treatment Victoza has been recommended for approval in Europe, in an important boost for the Danish company.

The European Medicines Agency said on Friday it had issued a positive opinion for Xultophy, previously known as IDegLira, implying the medicine is likely to be formally approved by the European Commission within three months.

Read more

To category page

Loading...